Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer

 

EDITOR - IN - CHIEF

Dimitrios H. Roukos, MD, PhD

Emeritus Professor of Cancer Precision Medicine

Founding Director:
* Center for Biosystems and Genome Medicine
 
  Ioannina University, School of Medicine
Biomedical Research Foundation Academy of Athens (BRFAA)
* Systems Biology Unit
 
Publications: 257 papers in PubMed including 100 on clinical cancer genome analysis applying Next - Generation Sequencing, molecular interactions regulatory networks and nonlinear transcriptional biocircuits for clinical implications as well as 48 on Precision Medicine - Oncology.
Citations: 10103 including 22 papers each with > 100 citations; h-index 79 (Scopus)
Updated February 2, 2021

Phones: +30 265100-5572/-7423 (Univ.); +302651099-695/-769 (Univ. Hospital)
E-mail: droukos@uoi.gr
            Website: www.gastricbreastcancer.com

 
SHORT CV  
Biosketch profile
Most Important papers on Cancer Precision Medicine
  Journal Year Impact Factor
JCR*
Citations
(Scopus)
1

Kyrochristos ID, Roukos DH. Comprehensive intra-individual genomic and transcriptional heterogeneity: Evidence-based Colorectal Cancer Precision Medicine. Cancer Treat Rev. 2019 Nov;80:101894. doi: 10.1016/j.ctrv.2019.101894

2019
8.3
2
2
Kyrochristos ID, Ziogas DE, Roukos DH. Dynamic genome and transcriptional network-based biomarkers and drugs: precision in breast cancer therapy. Med Res Rev. 2019 May;39(3):1205-1227. doi: 10.1002/med.21549. Epub 2018 Nov 11. Review.
2019
9.8
6
3
2019
6.9
4
4
2017
6.9
46
5
2016
6.9
40
6
2018
6.9
9
7
2010
3.1
116
8

Kyrochristos ID, Ziogas DE, Goussia A, Glantzounis GK, Roukos DH. Bulk and Single-Cell Next-Generation Sequencing: Individualizing Treatment for Colorectal Cancer. Cancers (Basel). 2019 Nov 18;11(11). pii: E1809. doi: 10.3390/cancers11111809. Review.

2019
6.2
-
9
2017
4.2
24
10
2017
2.3
4
* Journal Citation Reports by Clarivate Analytics 2018 - 2019
 
SELECTED CITATIONS IN HIGH-IMPACT JOURNALS
  PAPER CITATION Impact Factor
1
Roukos DH, Briasoulis E. Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome. Nat Clin Pract Oncol. 2007 Oct;4(10):578-90. Review.
Zhang L, Jing D, Jiang N, et al. Transformable peptide nanoparticles arrest HER2 signalling and cause cancer cell death in vivo. Nat Nanotechnol. 2020 Jan 27.
33.407
2
Roukos DH, Murray S, Briasoulis E. Molecular Genetic Tools Shape a Roadmap Towards a More Accurate Prognostic Prediction and Personalized Management of Cancer. Cancer Biol Ther. 2007 Mar;6(3):308-12.
Ji X, Mukherjee S, Landi MT, et al. Protein-altering germline mutations implicate novel genes related to lung cancer development. Nat Commun. 2020 May 11;11(1):2220.
11.800
 
Roukos DH. Genome-wide association studies: How predictable is a person's cancer risk? Expert Rev Anticanc Ther. 2009; 9: 389-392.
 
3
Roukos DH, et al. Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations. Ann Surg Oncol. 2002 Dec;9(10):941-3.
Trusheim MR(1), Berndt ER, Douglas FL. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat Rev Drug Discov. 2007 Apr;6(4):287-93.
57.618
4
Lianos GD, Alexiou GA, et al, Roukos DH. The role of heat shock proteins in cancer. Cancer Lett. 2015 May 1;360(2):114-8.
Nieto MA, Huang RY, et al. EMT: 2016. Cell. 2016 Jun 30;166(1):21-45.
36.216
5
Lianos GD, Alexiou GA, et al, Roukos DH. The role of heat shock proteins in cancer. Cancer Lett. 2015 May 1;360(2):114-8.
Manasanch EE, Orlowski RZ. Proteasome inhibitors in cancer therapy. Nat Rev Clin Oncol. 2017 Jul;14(7):417-433.
34.106
6
Kyrochristos ID, Ziogas DE, Roukos DH. Dynamic genome and transcriptional network-based biomarkers and drugs: precision in breast cancer therapy. Med Res Rev. 2019 May;39(3):1205-1227.
Andrei L(1), Kasas S(2), Ochoa Garrido I(3), et al. Advanced technological tools to study multidrug resistance in cancer. Drug Resist Updat. 2020 Jan;48:100658.
11.708
7
Roukos, D.H., Kappas, A.M. Perspectives in the treatment of gastric cancer. (2005) Nature Clinical Practice Oncology, 2 (2), pp. 98-107.
Lu Y, Lemon W, Liu PY, et al. A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. PLoS Med. 2006 Dec;3(12):e467.
11.048
International Scientific Recognition as Leading Expert in Cancer Precision Medicine
Breakthrough Concepts
Evaluator in:
    International Projects
   
High-impact journals
Reviewer in high-impact journals (Nature Biotechnology, Nature Reviews Genetics, Lancet Oncology [13 reviews], Nature Reviews Clinical Oncology, Nature Communications, Nature Protocols) and multiple other journals.
Editorial Board Member (29)
Expertise in Precision Cancer Medicine
 
From a total > 100 papers on clinical cancer genome analysis applying NGS
 
48 on Precision Medicine - Oncology
Organizing Committee Member in International Meetings

ISSN : 1109 - 7647
   Print ISSN : 1109 - 7655

 

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.



Search only trustworthy HONcode health websites:

last update: 2 February 2021